{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T08:38:53Z","timestamp":1794559133201,"version":"4.9.1"},"reference-count":41,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,5,8]],"date-time":"2023-05-08T00:00:00Z","timestamp":1683504000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>To explore the effective dose to immune cells (EDIC) for better prognosis while avoiding radiation-induced lymphopenia (RIL) in patients with locally advanced esophageal squamous cell carcinoma (ESCC).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>Overall, 381 patients with locally advanced ESCC receiving definitive radiotherapy with or without chemotherapy (dRT \u00b1 CT) between 2014 and 2020 were included in this study. The EDIC model was calculated by radiation fraction number and mean doses to the heart, lung, and integral body. The correlation between EDIC and clinical outcomes was analyzed using Cox proportional hazards regression, and risk factors for RIL were determined by logistic regression analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The median EDIC was 4.38 Gy. Multivariate analysis revealed that low-EDIC significantly improved the OS of patients when compared with high-EDIC (HR = 1.614, P = 0.003) and PFS (HR = 1.401, P = 0.022). Moreover, high-EDIC was associated with a higher incidence of grade 4 RIL (OR = 2.053, P = 0.007) than low-EDIC. In addition, we identified body mass index (BMI), tumor thickness, and nodal stage as independent prognostic factors of OS and PFS, while BMI (OR = 0.576, P = 0.046) and weight loss (OR = 2.214, P = 0.005) as independent risk factors of grade 4 RIL. In subgroup analyses, the good group had better clinical outcomes than the remaining two groups (P&amp;lt; 0.001).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study demonstrated that EDIC significantly correlates with poor clinical outcomes and severe RIL. Optimizing treatment plans to decrease the radiation doses to immune cells is critical for improving the outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2023.1066255","type":"journal-article","created":{"date-parts":[[2023,5,8]],"date-time":"2023-05-08T00:25:44Z","timestamp":1683505544000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":24,"title":["Higher radiation dose on immune cells is associated with radiation-induced lymphopenia and worse prognosis in patients with locally advanced esophageal squamous cell carcinoma"],"prefix":"10.3389","volume":"14","author":[{"given":"Jianjian","family":"Qiu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hancui","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongmei","family":"Ke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yilin","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaying","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hejin","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qunhao","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongying","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingyun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiping","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiwei","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiancheng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,5,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21708","article-title":"Cancer statistics, 2022","volume":"72","author":"Siegel","year":"2022","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21731","article-title":"Cancer treatment and survivorship statistics, 2022","volume":"72","author":"Miller","year":"2022","journal-title":"CA Cancer J Clin"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.34158","article-title":"Global and national trends in the age-specific sex ratio of esophageal cancer and gastric cancer by subtype","volume":"151","author":"Wang","year":"2022","journal-title":"Int J Cancer"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.21037\/acs.2017.03.03","article-title":"Overview of esophageal cancer","volume":"6","author":"Abbas","year":"2017","journal-title":"Ann Cardiothorac Surg"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2017.48","article-title":"Oesophageal cancer","author":"Smyth","year":"2017","journal-title":"Nat Rev Dis Primers 3 17048"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1809697","article-title":"Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC","volume":"379","author":"Antonia","year":"2018","journal-title":"N Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)60643-6","article-title":"Oesophageal carcinoma","volume":"381","author":"Pennathur","year":"2013","journal-title":"Lancet"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1517\/14712598.2015.1114097","article-title":"Nivolumab for treating non-small cell lung cancer","volume":"15","author":"Guibert","year":"2015","journal-title":"Expert Opin Biol Ther"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709030","article-title":"Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma","volume":"377","author":"Weber","year":"2017","journal-title":"N Engl J Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1-Positive non-Small-Cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N Engl J Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)32517-X","article-title":"Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial","volume":"389","author":"Rittmeyer","year":"2017","journal-title":"Lancet"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30181-X","article-title":"Nivolumab treatment for oesophageal squamous-cell carcinoma: an open-label, multicentre, phase 2 trial","volume":"18","author":"Kudo","year":"2017","journal-title":"Lancet Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djs629","article-title":"Combining radiotherapy and cancer immunotherapy: a paradigm shift","volume":"105","author":"Formenti","year":"2013","journal-title":"J Natl Cancer Inst"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-02-206870","article-title":"Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment","volume":"114","author":"Lee","year":"2009","journal-title":"Blood"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-0037","article-title":"Toward precision radiotherapy for use with immune checkpoint blockers","volume":"24","author":"Vanpouille-Box","year":"2018","journal-title":"Clin Cancer Res"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1112824","article-title":"Immunologic correlates of the abscopal effect in a patient with melanoma","volume":"366","author":"Postow","year":"2012","journal-title":"N Engl J Med"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2017.05.037","article-title":"Lymphocyte nadir and esophageal cancer survival outcomes after chemoradiation therapy","volume":"99","author":"Davuluri","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3109\/07357907.2012.762780","article-title":"The etiology of treatment-related lymphopenia in patients with malignant gliomas: modeling radiation dose to circulating lymphocytes explains clinical observations and suggests methods of modifying the impact of radiation on immune cells","volume":"31","author":"Yovino","year":"2013","journal-title":"Cancer Invest"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2019.06.079","article-title":"Tumor remission and tumor-infiltrating lymphocytes during chemoradiation therapy: predictive and prognostic markers in locally advanced esophageal squamous cell carcinoma","volume":"105","author":"Qian","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13246193","article-title":"Higher radiation dose to the immune cells correlates with worse tumor control and overall survival in patients with stage III NSCLC: a secondary analysis of RTOG0617","volume":"13","author":"Jin","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2019.05.064","article-title":"Impact of radiation dose to the host immune system on tumor control and survival for stage III non-small cell lung cancer treated with definitive radiation therapy","volume":"105","author":"Ladbury","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B24","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/j.radonc.2016.04.025","article-title":"Impact of heart and lung dose on early survival in patients with non-small cell lung cancer treated with chemoradiation","volume":"119","author":"Tucker","year":"2016","journal-title":"Radiother Oncol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.jtho.2016.09.134","article-title":"Heart dose is an independent dosimetric predictor of overall survival in locally advanced non-small cell lung cancer","volume":"12","author":"Speirs","year":"2017","journal-title":"J Thorac Oncol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/j.radonc.2018.05.017","article-title":"Cardiac dose is associated with immunosuppression and poor survival in locally advanced non-small cell lung cancer","volume":"128","author":"Contreras","year":"2018","journal-title":"Radiother Oncol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2014.04.025","article-title":"Lymphopenia association with gross tumor volume and lung V5 and its effects on non-small cell lung cancer patient outcomes","volume":"89","author":"Tang","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B28","doi-asserted-by":"publisher","first-page":"19","DOI":"10.4143\/crt.2016.595","article-title":"The prognostic value of treatment-related lymphopenia in nasopharyngeal carcinoma patients","volume":"50","author":"Liu","year":"2018","journal-title":"Cancer Res Treat"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2018.07.456","article-title":"Lack of validation of lymphopenia as a prognostic factor in esophageal cancer chemoradiation","volume":"102","author":"Zhang","year":"2018","journal-title":"Int J Radiat OncologyBiologyPhysics"},{"key":"B30","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.radonc.2019.12.023","article-title":"Lymphopenia during radiotherapy in patients with oropharyngeal cancer","volume":"145","author":"Ng","year":"2020","journal-title":"Radiother Oncol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1007\/s12094-020-02345-3","article-title":"Radiation-induced lymphopenia: the main aspects to consider in immunotherapy trials for endometrial and cervical cancer patients","volume":"22","author":"Holub","year":"2020","journal-title":"Clin Transl Oncol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1080\/095530097142852","article-title":"Intrinsic radiosensitivity of healthy donors and cancer patients as determined by the lymphocyte micronucleus assay","volume":"72","author":"Slonina","year":"1997","journal-title":"Int J Radiat Biol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.radonc.2021.06.020","article-title":"Impact of effective dose to immune cells (EDIC) on lymphocyte nadir and survival in limited-stage SCLC","volume":"162","author":"Yu","year":"2021","journal-title":"Radiother Oncol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01836","article-title":"Metastatic latency, a veiled threat","volume":"10","author":"Kim","year":"2019","journal-title":"Front Immunol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/bs.acr.2016.07.002","article-title":"The relationship between dormant cancer cells and their microenvironment","volume":"132","author":"Linde","year":"2016","journal-title":"Adv Cancer Res"},{"key":"B36","doi-asserted-by":"publisher","first-page":"597","DOI":"10.3390\/vaccines3030597","article-title":"Cancer dormancy: a regulatory role for endogenous immunity in establishing and maintaining the tumor dormant state","volume":"3","author":"Baxevanis","year":"2015","journal-title":"Vaccines (Basel)"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.21037\/acs.2017.03.14","article-title":"8th edition AJCC\/UICC staging of cancers of the esophagus and esophagogastric junction: application to clinical practice","volume":"6","author":"Rice","year":"2017","journal-title":"Ann Cardiothorac Surg"},{"key":"B38","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.radonc.2020.02.002","article-title":"The prognostic value of volumetric changes of the primary tumor measured on cone beam-CT during radiotherapy for concurrent chemoradiation in NSCLC patients","volume":"146","author":"Kwint","year":"2020","journal-title":"Radiother Oncol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2017.12.011","article-title":"A competing risk model of first failure site after definitive chemoradiation therapy for locally advanced non-small cell lung cancer","volume":"13","author":"Nygard","year":"2018","journal-title":"J Thorac Oncol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.radonc.2020.04.054","article-title":"Ultra-high dose rate effect on circulating immune cells: a potential mechanism for FLASH effect","volume":"149","author":"Jin","year":"2020","journal-title":"Radiother Oncol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2017.06.2450","article-title":"Comparative outcomes after definitive chemoradiotherapy using proton beam therapy versus intensity modulated radiation therapy for esophageal cancer: a retrospective, single-institutional analysis","volume":"99","author":"Xi","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1066255\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,8]],"date-time":"2023-05-08T00:25:47Z","timestamp":1683505547000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1066255\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,8]]},"references-count":41,"alternative-id":["10.3389\/fimmu.2023.1066255"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2023.1066255","relation":{"has-part":[{"id-type":"doi","id":"https:\/\/doi.org\/10.3389\/fimmu.2023.1066255.s001","asserted-by":"subject"}]},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,8]]},"article-number":"1066255"}}